
==== Front
BMC Med
BMC Med
BMC Medicine
1741-7015
BioMed Central London

39227839
3583
10.1186/s12916-024-03583-w
Research
A functional variant rs912304 for late-onset T1D risk contributes to islet dysfunction by regulating proinflammatory cytokine-responsive gene STXBP6 expression
Qian Yu 1
Chen Shu 12
Wang Yan 1
Zhang Yuyue 1
Zhang Jie 1
Jiang Liying 1
Dai Hao 1
Shen Min 1
He Yunqiang 1
Jiang Hemin 1
Yang Tao 1
Fu Qi drfuqi@njmu.edu.cn

1
Xu Kuanfeng kuanfengxu@njmu.edu.cn

1
1 https://ror.org/04py1g812 grid.412676.0 0000 0004 1799 0784 Department of Endocrinology and Metabolism, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029 China
2 https://ror.org/05pdn2z45 Department of Endocrinology, Affiliated Hospital 2 of Nantong University, Nantong First People’s Hospital, Nantong, 226000 China
4 9 2024
4 9 2024
2024
22 35720 3 2024
23 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

Our previous genome‑wide association studies (GWAS) have suggested rs912304 in 14q12 as a suggestive risk variant for type 1 diabetes (T1D). However, the association between this risk region and T1D subgroups and related clinical risk features, the underlying causal functional variant(s), putative candidate gene(s), and related mechanisms are yet to be elucidated.

Methods

We assessed the association between variant rs912304 and T1D, as well as islet autoimmunity and islet function, stratified by the diagnosed age of 12. We used epigenome bioinformatics analyses, dual luciferase reporter assays, and expression quantitative trait loci (eQTL) analyses to prioritize the most likely functional variant and potential causal gene. We also performed functional experiments to evaluate the role of the causal gene on islet function and its related mechanisms.

Results

We identified rs912304 as a risk variant for T1D subgroups with diagnosed age ≥ 12 but not < 12. This variant is associated with residual islet function but not islet-specific autoantibody positivity in T1D individuals. Bioinformatics analysis indicated that rs912304 is a functional variant exhibiting spatial overlaps with enhancer active histone marks (H3K27ac and H3K4me1) and open chromatin status (ATAC-seq) in the human pancreas and islet tissues. Luciferase reporter gene assays and eQTL analyses demonstrated that the biallelic sites of rs912304 had differential allele-specific enhancer activity in beta cell lines and regulated STXBP6 expression, which was defined as the most putative causal gene based on Open Targets Genetics, GTEx v8 and Tiger database. Moreover, Stxbp6 was upregulated by T1D-related proinflammatory cytokines but not high glucose/fat. Notably, Stxbp6 over-expressed INS-1E cells exhibited decreasing insulin secretion and increasing cell apoptosis through Glut1 and Gadd45β, respectively.

Conclusions

This study expanded the genomic landscape regarding late-onset T1D risk and supported islet function mechanistically connected to T1D pathogenesis.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12916-024-03583-w.

Keywords

T1D
Stxbp6
Islet function
Islet autoimmunity
Variant
issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcBackground

Type 1 diabetes (T1D) is an autoimmune disease caused by the destruction of pancreatic β cells and the absolute insufficiency of insulin [1], which has been increasing worldwide for several decades [2]. T1D is a multifactorial disease, with immune, genetic, viral, and environmental factors contributing to its development [3]. As the initial trigger of T1D [4, 5], over 80 non-HLA regions have been reported to be associated with T1D risk [5–7] except for the HLA risk region (especially HLA-DR-DQ on 6p21) [5]. Studies also indicate that multiple non-HLA risk regions influence the risk for islet autoimmunity [8–10]. As an autoimmune disease, most T1D candidate genes were functionally related to immune responses, such as CTLA4, IL-2RA, PTPN2, and CD226 [5]. However, cumulative evidence supports a role for islet β-cell function in T1D pathogenesis [11]. Several candidate genes in T1D non-HLA risk regions, such as INS, GLIS3, CTSH, and CLEC16A, were reported to affect islet function [12]. Our previous study [13] also indicated that the genetic risk score (GRS) affected fasting C-peptide levels in newly diagnosed T1D individuals.

Syntaxin binding protein 6 (STXBP6), the sixth member of the syntaxin-binding protein family, is located in 14q12, which is a vital part of the SNAP receptor (SNARE) complex and is crucial in neuronal vesicle trafficking [14]. A prior study has reported that SOX4 affected extracellular insulin delivery by regulating STXBP6 expression [15, 16], which is related to glucose-stimulated insulin secretion by participating in the expansion of fusion pores during the insulin exocytosis process [15, 16]. Vujkovic et al. demonstrated that 14q12 was a T2D risk region, with the leading GWAS-significant variant rs11159347 near STXBP6 [17]. Scanning from our previous T1D GWAS [13], rs912304, another independent leading variant in STXBP6, was found to be associated with T1D risk. However, it remains to be determined whether rs912304 or its high linkage disequilibrium (LD) variant is functionally related to T1D and its related mechanism.

Therefore, this study investigated the association between the variant rs912304 and T1D subgroups and related clinical indicators, including islet autoimmunity and islet function. We further assessed the functional variant(s) and implacted gene(s) in 14q12. Finally, we evaluated the role of the putative causal gene on islet function and its related mechanism.

Methods

Study participants

A total of 2423 T1D and 5082 subjects were enrolled in the study. As previously described [13], we recruited 1045 T1D and 1308 healthy individuals for GWAS scanning, and the validation subjects consisted of 1378 patients and 3774 controls recruited from southeastern, central, and southern China. Only patients diagnosed with insulin-dependent diabetes mellitus within six months and having at least one positive autoantibody were included in the T1D subjects. Controls were outpatients from the same region with no diabetes and no family history of diabetes. All samples were collected with appropriate informed consent from all participants or guardians. The study was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University and was conducted following the principles of the Declaration of Helsinki.

Laboratory measurements for glycemic traits and islet‑specific autoantibodies

A total of 2353 non-diabetic controls from the validation stage measured plasma glucose and serum insulin levels at fasting, 30 min, and 120 min based on an oral glucose tolerance test (OGTT). The plasma glucose and serum insulin levels were measured using a fully automated biochemical analyzer (Roche, Switzerland) and insulin radioimmunoassay kit (BMIBT, China). Insulinogenic Index (IGI) and corrected insulin response (CIR) were used as indicators of insulin release stimulated by oral glucose, while insulin sensitivity was evaluated using ISI Matsuda and other indices. Next, a mixed meal glucose tolerance test (MMTT) was performed on the 202 newly diagnosed T1D individuals. This test was not required for T1D patients with fasting C-peptide levels ≤ 25 pmol/L, but only the fasting C-peptide level was measured by chemiluminescence (Roche Diagnostics, Switzerland). In addition, islet-specific autoantibodies, including ZnT8A, GADA, and IA-2A, were measured when T1D subjects enrolled, which was detected separately by radioimmunoassay, as previously described [13].

Genotyping assay

Genomic DNA was extracted from peripheral blood lymphocytes using the QIAamp DNA blood extraction kit (QIAGEN, Germany). Genotyping of rs912304 in STXBP6 was from two aspects: 1045 T1D and 1308 healthy individuals were extracted for this variant in the T1D GWAS screening section [13]. The validated 1378 T1D and 3774 subjects were genotyped using TaqMan assays (Applied Biosystems). The distributions of genotypes in healthy and T1D subjects were in accordance with the Hardy–Weinberg equilibrium (P > 0.05).

In silico annotation of the functional variant and casual gene

For the potential functional variants, we performed with RegulomeDB v.2 [18], a tool incorporating genomic assays (TF ChIP-seq and DNase-seq from the ENCODE database and those overlapping the footprints and QTL data), to prioritize functional variant(s) located within 14q12. We also verified the results of functional predictions using HaploReg v4.2 [19], which utilized epigenomics data (chromatin states and histone H3 marks) primarily from Roadmap Epigenomics and ENCODE projects.

To prioritize the most causal gene in 14q12, we first annotated using our Variant-to-Gene (V2G) pipeline using Open Targets Genetics [20], which integrates molecular phenotype quantitative trait loci experiments, chromatin interaction experiments, variant effect predictor (VEP) from Ensembl, the distance between the variant and each gene’s canonical transcription start site (TSS), etc. We further identified the top-ranked eQTL gene using a meta-analysis P value of multi-tissues from GTEx v8 [21], confirmed by Tiger, Translational human pancreatic Islet Genotype tissue-Expression Resource [22].

Dual-luciferase reporter gene assay

Dual luciferase reporter gene assays were performed to assess whether the double-stranded oligonucleotide containing either G or T allele at the variant rs912304 showed different enhancer activity. DNA fragments covering the G or T allele at rs912304 (hg38 Chr14:25,006,964) were amplified, and constructed into the pGL3-promoter plasmids. The pGL3-promoter plasmid with DNA fragment containing either G or T allele, or empty pGL3-promoter vector in equal amounts was transiently co-transfected into HEK-239 T, INS-1E and MIN6 cell lines with pRL-TK plasmid using Lipofectamine 3000 transfection reagent (Invitrogen). Twenty-four hours post-transfection, cells were collected, and luciferase activity was measured by Dual-Luciferase Reporter Assay System (Promega). Firefly luciferase activity was expressed as relative luciferase units (RLU) after correction for Renilla luciferase activity to adjust for transfection efficiency. Data were normalized to those cells transfected with empty pGL3-Promoter vector. All assays were performed with a minimum of four replications in at least three independent experiments.

Cell culture and treatment

Isolation and culture of primary mouse islets, mouse β-cell lines (MIN6 and β-TC6), and HEK-293 T cells were performed as previously described [23]. The rat β-cell line INS-1E (donated by Prof. Xiao Han from Nanjing Medical University) was cultured in RPMI-1640 medium (11 mM glucose) containing 10% FBS, sodium pyruvate (1 mmol/L), HEPES (10 mmol/L), penicillin (100 U/mL), streptavidin (100 μg/mL), β-mercaptoethanol (50 μmol/L), and L-glutamine (2 mmol/L).

T1D-related cytokines consisted of 5 ng/ml IL-1β, 100 ng/ml INF-γ and 10 ng/ml TNF-α, respectively. A mixture of the three cytokine mixes was added to the complete medium of MIN6 cells, INS-1E cells, and β-TC-6 cells, respectively, according to the amount needed. The cells were spread in the culture plate at a density of about 1 × 106 cells/ml and then incubated in a constant temperature and humidity incubator (containing 5% CO2) at 37 °C. Upon reaching approximately 70% confluency, the cell culture medium was replaced with cytokines or free medium. In addition, high glucose (20 mM glucose) and high FFA (0.5 mM palmitic acid) were treated in INS-1E with a similar procedure. RNA and protein samples were accordingly collected after 48 h of incubation.

siRNA transfection and recombinant adenovirus infusion

MIN6 cells were seeded in 24-well plates and cultured until they reached 70% confluence. Transient transfection with siRNA targeting the Stxbp6 gene was done using Lipo3000 (Life Technologies, USA). All assays were performed 48 h after transfection. INS-1E cells were seeded in 6-well or 24-well plates and cultured until they reached 70% confluence. The cell culture medium was replaced the next day by one containing empty or Stxbp6 recombinant adenovirus (AdMax system), the amount of virus added per ml of cell culture medium = MOI × cell numers × 103/virus titer), and the medium was changed after 6 h of transfection according to the cell status. After 48 h of incubation, the samples were collected, and the corresponding RNA and protein were extracted. SiRNA and recombinant adenovirus were purchased from Shanghai GenePharma CO. LTD and Shanghai OBio Tech CO. LTD, respectively.

GSIS functional assay

Transfected INS-1E were grown in 24-well plates and treated for 48 h accordingly. In brief, we added glucose to Kreb’s buffer to make 2 mM and 20 mM glucose solution and then discarded the solution after incubating them with glucose-free Kreb’s buffer for 60 min. Next, we added 500 μl 2 mM and 20 mM glucose solution per well and incubated for 60 min, collected the supernatant, centrifuged at 4 ℃, 3000 rpm, 15 min, and aspirated the supernatant, and stored at – 80 ℃. Finally, the cell culture supernatant was measured using insulin ELISA kits (MS300, Ezassay, China).

TUNEL assay

For quantifying cell apoptosis after adenovirus transfection, TUNEL staining was performed with YF594 TUNEL Assay Apoptosis Detection Kit (US Everbright, China) in INS-1E cells according to the instructions.

Bulk RNA sequencing

RNA-seq methods have been previously described [23]. Briefly, total RNA was extracted from INS-1E using TRIzol reagent (Invitrogen, CA, USA) according to the manufacturer's instructions. On-chip electrophoresis was used to measure the quality and quantity of extracted RNA using the Agilent RNA 6000 Nano Kit and Agilent 2100 Bioanalyzer (Agilent Technologies, CA, USA). Library preparation was performed on samples exhibited 1.9 ≤ A260/A280 ≤ 2.2, RNA integrity number > 8.0, and 28S/18S > 1.0. By enriching poly (A) mRNA with magnetic oligo (dT) beads, total RNA was purified. With the random hexamer (N6) primers, double-stranded cDNA fragments were synthesized and subjected to end repair and adapter ligation. Next, PCR amplification was used to construct cDNA libraries sequenced on BGISEQ-500 by BGI CO. LTD (Wuhan, China). Gene expression was quantified using RSEM 1.1.12 software and normalized using the method of fragments per kilobase of exon model per million reads mapped (FPKM). DEseq2 (logFC ≥ 0.5 and adjusted p ≤ 0.05) was used to identify differentially expressed genes (DEGs) between the Stxbp6 over-expressed and control groups.

q‑PCR

Total mRNA was extracted from tissues and cells using TRIzol reagent (Life Technologies). RNA from each sample was reverse transcribed using PrimeScript™ RT reagent kit (Takara Bio, Kusatsu, Japan). qRT-PCR was performed with SYBR Green PCR Master Mix (Takara Biotechnology) and analyzed using a real-time PCR system (StepOneplus, ABI). The relative gene expression was calculated using the comparative CT (2 − ΔΔCT) method with GAPDH as a reference gene. The primer sequences used are listed in Additional file 1: Table S1.

Western blotting

Cell lysates were prepared using RIPA lysis buffer on ice. The protein concentration was measured using the bicinchoninic acid (BCA) Assay Kit (Beyotime). WB was performed using the indicated antibodies (STXBP6 Polyclonal antibody, 10,976–4-AP, Proteintech; β-tubulin Polyclonal antibody, 10,068–1-AP, Proteintech; Caspase 3 Polyclonal antibody, 19,677–1-AP, Proteintech; Cleaved Caspase 3 Polyclonal antibody, 25,128–1-AP, Proteintech; ENO2 Monoclonal antibody, 66,150–1-Ig, Proteintech; GLUT1 Polyclonal antibody, 21,829–1-AP, Proteintech; GADD45B Antibody, DF2375, Affinity). Protein blots were visualized using SuperSignal West Pico Chemiluminescent Substrate (Pierce Biotechnology) in a ChemiDoc XRS + system (Bio-Rad Laboratories).

Statistical analysis

The frequencies of allele and genotype were assessed by direct counting. Associations between the variant and T1D risk in the case–control study and departures from the Hardy–Weinberg equilibrium (HWE) were analyzed by the χ2 test. After testing for heterogeneity, a combined meta-analysis was performed using the Mantel–Haenszel (fixed-effects) and DerSimonian and Laird (random-effects) tests. The association of different genotypes with T1D risk was estimated using odds ratio (OR) tests with 95% CI. The heterogeneity between T1D subgroups was performed using Cochran’s Q test, considered significant with I2 ≥ 75% and P ≤ 0.05. The additive model examined associations for glycemic quantitative traits using logistic regression analysis. Values of serum insulin, HOMA-B, IGI, CIR, HOMA-IR, and ISIMatsuda were logarithmically transformed. The student's unpaired two-tailed t-test or Mann–Whitney test was used for pairwise comparisons depending on whether the data followed a Gaussian distribution. One-way ANOVA, or the Kruskal–Wallis test, was used for more than two groups. Error bars represent mean ± SD. P values were considered statistically significant with a P value of < 0.05. These statistical analyses were performed using SPSS 18.0, Stata11.0, and GraphPad Prism 9.0 software.

Results

Rs912304 in 14q12 is a risk variant for T1D subgroups with diagnosed age ≥ 12 years old

In our previous T1D GWAS, 14q12 regions were associated with T1D risk with the leading variant rs912304 (Additional file 1: Table S2). In a further case–control study, we first replicated and validated the association between rs912304 and T1D (P = 0.0177). Combined results with the GWAS scanning showed this variant was associated with T1D risk (OR (95% CI) = 1.18 (1.09–1.27), P = 1.29E − 05) (Table 1). We further analyzed T1D subjects stratified by the age of T1D diagnosis and found that this variant was a suggestive risk variant for those diagnosed age ≥ 12 years old (OR (95% CI) = 1.21 (1.12–1.31), P = 2.54E − 06), but not those diagnosed age < 12 (OR (95% CI) = 1.05 (0.94–1.17), P = 0.377). A significant heterogeneity was observed between these two subgroups (I2 = 76.6%, P = 0.039). We also stratified T1D subjects according to the number of autoantibodies and found that rs912304 was associated with single (OR (95% CI) = 1.17 (1.07–1.27), P = 1.75E − 04) and multiple (OR (95% CI) = 1.14 (1.04 − 1.26), P = 1.03E − 02) antibody-positive T1D individuals without heterogeneity (I2 = 0, P = 0.692) (Table 2). In addition, some T2D subjects might be misclassified as late-onset T1D [24]. T1D subjects diagnosed age ≥ 12 were stratified by autoantibody status, and we found that both the subjects with multiple autoantibodies and those with single autoantibodies showed significant association with the variant rs912304 without any heterogeneity (Additional file 1: Table S3). Table 1 The association between rs912304 in STXBP6 and T1D risk

Stage	Genotype distribution (GG/GT/TT)	MAF(%)	Additive model	
Cases	Controls	Cases	Controls	OR (95%CI)	P value	
Discovery	278/512/215	435/603/219	46.9	41.4	1.28 (1.13-1.45)	9.59E-05	
Replication	458/759/302	946/1389/510	44.9	42.3	1.11 (1.01-1.21)	0.0177	
Combined	736/1271/517	1381/1992/729	45.7	42.1	1.18 (1.09-1.27)	1.29E-05	
MAF minor allele frequency. G allele, the reference allele; T allele, the effect allele

Table 2 The association between rs912304 in STXBP6 and T1D subgroups stratified by islet-specific autoantibody status and age at T1D diagnosis

Groups	Subgroups	Genotypes	Additive model	Heterogeneity	
GG	GT	TT	OR(95%CI)	P value	I2 (%)	P value	
Control		1381	1922	729					
T1D	Multi Abs+	313	497	217	1.14 [1.04,1.26]	1.03E-02	0	0.692	
Single Ab+	423	774	300	1.17 [1.07,1.27]	1.75E-04	
≥12	504	889	387	1.21 [1.12,1.31]	2.54E-06	76.6	0.039	
＜12	232	382	130	1.05 [0.94,1.17]	0.377	
Multi Ab+, at least two autoantibodies were positive among ZnT8A, GADA, and IA-2A; Single Ab+, only one autoantibody-positive among ZnT8A, GADA, and IA-2A. ≥12 and <12 mean the T1D subjects were diagnosed with age ≥12 and <12 years old, respectively

Rs912304 affects residual islet function in T1D individuals of diagnosed age ≥ 12 years old

We next evaluated the impact of the variant rs912304 on islet function indexes in healthy individuals based on OGTT. This variant was significantly correlated with CIR and DI (P = 0.007 and 0.047, respectively) (Table 3). Subsequently, we assessed its effect on residual β-cell function in newly diagnosed T1D individuals, and it was correlated with fasting C-peptide level (P = 0.0289) (Fig. 1A) not the AUC of 2-h C-peptide level (Fig. 1D). After further stratified by the age of T1D diagnosis, this variant was significantly associated with fasting and AUC of 2-h C-peptide level (P = 0.0186, and 0.0298, respectively) (Fig. 1C, F) in T1D subjects with diagnosed age ≥ 12, which was consistent with their association with residual β-cell function (≥ 200 pmol/L) in this subgroup (P = 0.037) (Additional file 1: Table S4). However, no such correlation was found in those diagnosed age < 12 (Fig. 1B, E; Additional file 1: Table S4). In addition, we also investigated whether this variant affects the positive rate of islet-specific autoantibodies in T1D subjects, but no significant correlation was observed (Fig. 1G–I, Additional file 1: Table S5). Table 3 The correlation between rs912304 and glycemic quantitative traits in 2353 healthy individuals based on OGTT

Traits	GG	GT	TT	β	SE	P	P-adj	
n (men/women)	775 (207/568)	1,148 (297/851)	430 (100/330)	0.017	0.013	0.187		
Age (years)	54.2 ± 8.8	54.3 ± 9.2	54.3 ± 8.8	0.054	0.265	0.84		
BMI (kg/m2)	22.3 ± 2.0	22.2 ± 2.0	22.3 ± 2.0	-0.047	0.059	0.425		
Plasma glucose (mmol/l)	
 Fasting	5.17 ± 0.27	5.17 ± 0.27	5.15 ± 0.28	-0.009	0.008	0.179	0.239	
 30 min post OGTT	8.30 ± 1.39	8.21 ± 1.41	8.09 ± 1.42	-0.094	0.041	0.015	0.021	
 120 min post OGTT	6.06 ± 0.98	5.99 ± 0.98	5.98 ± 0.99	-0.045	0.028	0.136	0.109	
Serum insulin (mIU/l)	
 Fasting	9.44 (6.89-12.63)	9.38 (7.19-12.76)	9.74 (7.12-13.04)	0.007	0.006	0.332	0.29	
 30 min post OGTT	52.86 (34.87-80.7)	53.48 (34.90-81.71)	53.68 (36.92-83.77)	0.008	0.008	0.342	0.304	
 120 min post OGTT	38.85 (24.98-58.15)	38.02 (24.82-57.79)	37.14 (24.01-58.62)	-0.007	0.009	0.46	0.433	
Islet function	
 HOMA-β	111.3 (84.3-158.9)	115.6 (85.1-156.2)	118.6 (84.7-163.1)	0.01	0.007	0.169	0.16	
 IGI	14.48 (8.44-24.9)	15.03 (9.15-25.48)	15.88 (8.99-27.14)	0.019	0.011	0.09	0.085	
 CIR	153.92 (91.93-247.67)	161.45 (99.25-265.84)	177.05 (102.71-294.23)	0.026	0.01	0.007	0.007	
Insulin resistance	
 HOMA-IR	2.19 (1.59-2.93)	2.18 (1.63-2.92)	2.21 (1.61-2.98)	0.006	0.007	0.411	0.354	
 ISIc	5.19 (3.89-7.06)	5.25 (3.95-7.03)	5.22 (3.86-6.79)	-0.003	0.006	0.682	0.616	
Disposition indexes	67.90 (42.76-115.13)	72.72 (44.13-124.33)	73.56 (46.69-126.39)	0.02	0.01	0.038	0.047	
The risk allele beta coefficients (SE) corresponding to the effect sizes were calculated using a linear regression analysis under an additive model. The analysis of insulin levels and islet function-related indicators at different time points were logarithmically transformed before analysis

IGI the insulinogenic index, CIR corrected insulin response, ISIc Matsuda’s insulin sensitivity index, DI disposition indexes, derived from IR/HOMA-IR

Fig. 1 The relationship between the variant rs912304 and residual islet function and islet autoimmunity in T1D individuals. A-C The association between rs912304 and fasting C-peptide level in total newly diagnosed T1D subjects, those diagnosed age <12 and ≥12 years old, respectively. D-F The association between rs912304 and 2-hour C-peptide AUC in total newly diagnosed T1D subjects, those diagnosed age <12 and ≥12 years old, respectively. G-I The association between rs912304 and the positive rate of ZnT8A, GADA, and IA-2A in total T1D subjects. The genotype distribution of rs912304 in newly diagnosed T1D subjects: GG = 52, TG = 102, TT = 48; T1D subjects with diagnosed age <12: GG = 10, TG = 26, TT = 8; and T1D subjects with diagnosed age ≥12: GG = 42, TG = 76, TT = 40. The genotype distribution of rs912304 in islet autoimmunity: GG=616, GT=1004, TT=420 for ZnT8A; GG=644, GT=1061, TT=443 for GADA; GG=639, GT=1059, TT=443 for IA-2A. The above correlations were analyzed by linear regression analysis and were corrected for sex and duration of T1D disease. Data are mean with 95%CI. *P<0.05 was considered as significant

Rs912304 is a functional variant regulating STXBP6 expression in islets

We evaluated the potential functional variant(s) in 14q12 risk regions. We first used RegulomeDB to prioritize functionally important variants within high linkage disequilibrium (LD, r2 ≥ 0.8) to rs912304. Among the twelve high LD variants, six (rs912304 and the other five variants) were ranked 1d-1f with high posterior probability (scores > 0.5) (Additional file 1: Table S6). Next, we verified the results of functional predictions using HaploReg v4.2 [19], which utilized epigenomics data (chromatin states and histone H3 marks) primarily from Roadmap Epigenomics and ENCODE projects. In this dataset, we found that only rs912304 exhibited spatial overlap with enhancer, an active chromatin state, in tissues related to islet function (both pancreas and pancreatic islets) (Fig. 2A, Additional file 1: Table S7). It co-localized more specifically with an enhancer region marked by H3K4me1 broad peaks in the pancreas and pancreatic islets (Fig. 2A). Further functional follow-up in the published bulk islets dataset [25, 26], we also found that rs912304 mapped to ATAC-Seq peaks (Fig. 2B). Collectively, rs912304 is the most potential functional variant in pancreatic tissue and islets.Fig. 2 Rs912304 is a functional variant regulating STXBP6 expression in islet β-cells. A The overlaps between rs912304 and chromatin state, histone H3 marks in Roadmap Epigenomics and ENCODE projects. The color red means rs912304 exhibited spatial overlaps with peaks of epigenomics data (chromatin states or histone H3 marks), blue means no spatial overlaps, and grey means the data were missing. B UCSC genome browser data showed that ATAC-Seq peaks overlapped with a genomic sequence containing rs912304 in published human islets. The location of rs912304 is highlighted with the red line. C Stxbp6 is the most significant eQTL gene regulated by rs912304 in 404 human islets derived from the Tiger database, highlighted in red. D The plasmid constructs containing different alleles of rs912304 enhancer and STXBP6 gene promoter. E-G The transcriptional activity of STXBP6 promoter after transfected to HEK-293T, islet β cell line INS-1E, and MIN6, respectively. The transcriptional activity was detected by the luciferase dual reporter gene method. Data are mean±SD. P-values were calculated by t-test, and at least three independent replicates were performed in each group. **P<0.01; ***P<0.001

As intron variants likely affect gene regulation [7], we further assessed the most putative candidate gene regulated by rs912304. Predicted by Open Targets Genetics [20], we found that among the six assigned candidate genes, STXBP6 was functionally implicated as the top-ranked potential causal gene with the highest variant to gene (V2G) score (Additional file 1: Table S8). Multi-tissue eQTL comparison from the GTEx v8 database revealed that STXBP6 is the unique eQTL gene regulated by rs912304, with a meta-analysis P-value = 1.32871e − 77 (Additional file 2: Fig. S1). Tiger, an integrative dataset with 404 human islets [22], also showed that STXBP6 is the most significant eQTL gene (P = 8.6e − 3) affected by rs912304 (Fig. 2C). Then, we performed luciferase reporter assays in HEK-293 T cells and two widely used cellular models of the β-cell (rat INS-1E and mouse MIN6). The construct containing the G allele of rs912304 exhibited higher enhancer activity of the STXBP6 gene than that of the T allele in HEK-293 T (P < 0.001), INS-1E (P < 0.01), and MIN6 (P < 0.01) (Fig. 2D–G). These data indicate that rs912304 was the most functional variant in pancreatic islets, which regulated the candidate gene STXBP6 as an enhancer.

T1D-related proinflammatory cytokine, not high glucose or FFA, up-regulates Stxbp6 expression on islet beta cells

To investigate the effects of different stress on Stxbp6 expression in islet β cells, we simulated them with three conditions in vitro: inflammatory cytokine, high glucose (20 mM glucose), and high fat (FFA). Under high glucose or FFA, Stxbp6 expression was not altered in cultured INS-1E and MIN6 cell lines (Fig. 3A, B). The results were similar to those observed under similar conditions derived from the published GEO database (Additional file 2: Fig. S2). However, we reanalyzed single-cell RNA sequencing (scRNA-seq) in the Human Pancreas Analysis Program (HPAP) [27]. The results showed that STXBP6 expression was upregulated in islet beta cells of T1D subjects (Fig. 3C). Meanwhile, after stimulating with T1D-related proinflammatory cytokine (TNF-α, IL-1β, and IFN-γ), we observed that Stxbp6 mRNA level was increased in primary mouse islets, and three β-cell lines (INS-1E, MIN6, and β-TC6) (all P < 0.05), (Fig. 3D–G). These were consistent with the fact that the Stxbp6 protein level was upregulated in the islet β-cell line stressed with cytokines (P < 0.05) (Fig. 3H, I). These data suggested that Stxbp6 was specifically stimulated in islet beta cells by T1D-related cytokines but not high glucose or lipids.Fig. 3 Stxbp6 is significantly upregulated in pancreatic islet β-cells stimulated with T1D-related proinflammatory cytokines. A-B The alternation of Stxbp6 mRNA levels in INS-1E and MIN6 under high glucose (20mM glucose) and high lipid (0.5mM palmitic acid) stimulation. C The difference of STXBP6 mRNA expression in human islets from nPOD. AAB means islet antibody-positive normoglycemic population. D-G The mRNA level of Stxbp6 in primary mouse islets, INS-1E, MIN6, and β-TC6 cell lines after stimulation with mouse/rat cytokines (5 ng/ml IL-1β, 100 ng/ml INF-γ and 10 ng/ml TNF-α) for different periods. H-I Alternation of Stxbp6 protein level in INS-1E and MIN6 cell lines after 6 and 24 h stimulation with the above proinflammatory cytokines. Data are mean±SD. P-values were calculated by t-test, and at least three independent replicates were performed in each group. *P<0.05; **P<0.01; ***P<0.001

Stxbp6 promotes β-cell apoptosis and inhibits insulin secretion via regulating Gadd45β and Glut1 expression respectively

We first over-expressed Stxbp6 in INS-1E cells with recombinant adenovirus to assess its effect on apoptosis. Over-expression of Stxbp6 did not affect apoptosis-associated protein Caspase 3 but significantly increased the expression of cleaved Caspase 3 (Fig. 4A). The apoptosis detection by TUNEL assay also revealed a significant increase in the Stxbp6 overexpression group (Fig. 4B) in INS-1E cells, suggesting that the Stxbp6 has a role in promoting apoptosis in pancreatic β-cells. Furthermore, although no significant change in the transcript levels of Ins1 and Ins2 was observed in the Stxbp6 overexpressed INS-1E cells (Fig. 4C), insulin secretion, not intracellular insulin content, was suppressed under high glucose stimulation conditions (P < 0.05) (Fig. 4D, E).Fig. 4 Effect of Stxbp6 overexpression on apoptosis, insulin synthesis, and secretion in INS-1E cells. A Protein expression of Stxbp6, Caspase 3 and cleaved- Caspase 3 in INS-1E cells treated with Stxbp6 recombinant adenovirus. The relative change of protein was calculated on the right. B Apoptosis detection by TUNEL assay. Scale bar 100μm. C Changes in insulinogenic gene Ins1/Ins2 mRNA levels after overexpression of Stxbp6 in INS-1E cell. D Insulin secretion at glucose concentrations of 2 mM and 20 mM, respectively; E, Intracellular insulin levels after overexpression of Stxbp6. Data are mean±SD. P-values were calculated by t-test, and at least three independent replicates were performed in each group. *P<0.05; **P<0.01; ***P<0.001

Further RNA sequencing revealed that 67 and 285 genes were significantly down-regulated or up-regulated in Stxbp6 overexpressed INS-1E cells (RPKM > 1) (Fig. 5A, B). Pathway enrichment analysis revealed that the downstream genes regulated by the Stxbp6 gene were significantly enriched in insulin secretion and the p53 signaling pathway (Fig. 5C, Additional file 1: Table S9). We validated the RNA-seq results and showed that about half of the downstream genes were associated with cell survival and apoptosis (e.g., Cdk2, Gadd45β, and Tp73; Fig. 5D), insulin secretion (e.g., Eno2 and Slc2a1; Fig. 5E), and other related genes (e.g., Cxcl12, Cygb, and Mgarp; Additional file 2: Fig. S3A, B). Knockdown of Stxbp6 with SiRNA (Si-332) in cytokine-stimulated MIN6 cells (Additional file 2: Fig. S3C), we found that mRNA levels of genes related to apoptosis (Cdk2 and Gadd45β, Fig. 5F), endocrine system (Slc2a1, Fig. 5G), immune system, and other signaling pathways (e.g., Cxcl12, Additional file 2: Fig. S3D, E). We further verified the apoptosis- and islet-function-related genes, consistent in both overexpression and knockdown experiments at the protein level. We found that the expression level of the Gadd45β was significantly increased in INS-1E cells after the overexpression of the Stxbp6 (P < 0.01), suggesting that Gadd45β was associated with Stxbp6 induced apoptosis in INS-1E cells. In addition, while Eno2 did not change significantly, the expression of Glut1 decreased significantly (P < 0.01), suggesting that the Glut1 was associated with Stxbp6-mediated reduction of insulin secretion in INS-1E cells (Fig. 5H).Fig. 5 Gadd45β and Glut1 are two key downstream genes regulated by Stxbp6 in islet β-cell lines. A Volcano plot of recombinant adenovirus overexpressing Stxbp6 gene in INS-1E cells with downstream differential gene expression. Red dots represent genes with rising differential expression, and blue dots represent genes with falling differential expression. DEGs were screened using logFC>0.5, FPKM>1, P-adj<0.05, Q value<0.1. B Heatmap of Stxbp6 gene downstream related genes based on RNA-Seq hints. C Analysis of pathway enrichment of DEGs using the KEGG database. D Effect of overexpression of Stxbp6 gene in INS-1E cells on cell proliferation and apoptosis genes. E Effect of overexpression of Stxbp6 gene in INS-1E cells on genes related to endocrine system. F-G Effect of knocking down Stxbp6 gene in MIN6 cells on genes related to the endocrine system and apoptosis. H Western blotting detection of protein expression of Gadd45β, Glut1, and Eno2 in INS-1E cells treated with Stxbp6 recombinant adenovirus. The relative change of protein was calculated on the right. Data are mean±SD. P-values were calculated by t-test, and at least three independent replicates were performed in each group. *P<0.05; **P<0.01; ****P<0.0001

Discussion

In this study, we first reveal that rs912304 in STXBP6 is a T1D risk variant associated with fasting and 2-h C-peptide levels in newly diagnosed T1D individuals diagnosed age over 12 years old. Next, rs912304, as an enhancer, functionally regulates STXBP6 expression in islet beta cells. Finally, Stxbp6 can inhibit insulin secretion and promote islet β-cell apoptosis by regulating Glut1 and Gadd45β expression.

Studies have observed an increasing incidence of adult T1D in multiple ethnicities [28] and revealed significant heterogeneities in T1D subgroups of age at T1D diagnosis [29]. Although LD score regression analysis showed a highly correlated genetic basis in early- and late-onset T1D individuals [13], our previous study demonstrated that HLA regions showed stronger effect sizes in early-onset T1D individuals [13]. Studies also identified unique risk regions and the same risk regions with more effect size in early-onset T1D individuals [30, 31]. Steck et al. [32] further found that non-HLA risk variants, such as rs6476839 in GLIS3, and rs4900384 near VRK1 were significantly associated with progression to T1D in individuals < 12 years old, whereas rs3184504 in SH2B3 was significant in those ≥ 12. This study revealed that rs912304 in STXBP6 is a suggestive non-HLA risk variant for late-onset T1D individuals (diagnosed age ≥ 12). These suggested further exploration with GWAS to hunt for more potential non-HLA risk regions for T1D subgroups with different diagnosed ages.

Prior studies demonstrated a shared genetic basis for T1D and islet-specific autoantibody positivity, such as rs1990760 in IFIH1 for IA-2A and rs12722495 in IL2RA for GADA positive rate [33, 34]. However, we found no significant association between rs912304 and the positivity of any islet-specific autoantibodies (ZnT8A, GADA, or IA-2A), indicating the variant did not affect islet autoimmunity. Multiple T1D genetic risk variants also affected islet function, for instance, rs3825932 in CTSH affected insulin secretion [35]. For the variant rs912304, prior studies have revealed its effect on 2-h glucose challenge [36] and HbA1C levels [37]. Our study found that rs912304 was associated with glucose-stimulated insulin secretion in healthy individuals based on OGTT, and further affected residual islet function in newly diagnosed T1D individuals, especially of diagnosed age ≥ 12. Thus, we speculated that rs912304 might contribute to T1D by regulating islet function.

For complex common diseases, multi-risk variants reaching GWAS significance are usually observed in a certain risk region, and the lead variant is not always the most likely one to be functional. Moreover, most risk regions contain multiple risk variants and candidate genes, making it crucial to identify the most functional variant and causal gene within these regions. Prior studies [7, 38, 39] have discovered the most functional variants and putative implicated genes for T1D risk using fine mapping, epigenetic data, etc. Studies also found that 14q12 was the risk region for white blood cell and monocyte count [40], rs2332462 and rs2038700 in STXBP6 (in high LD to rs912304) were predicted to be the most causal variants for these two counts, respectively. However, our study indicated that rs912304 is the most casual variant in pancreatic tissues or islets by overlapping with DNase I hotspots, H3K4me1, and ATAC-Seq. These implicated that different tissues might have different functional variants. In addition, from the ChIP-Seq experiments integrating into HaploReg v4.2 [19], DNA regions spanning rs912304 were found to bind two small MAF proteins (MAFF and MAFK), which regulate islet beta cell survival [41]. Regulatory motifs prediction by Position Weight Matrix (PWM) showed a different allele-specific alternation of this variant to pdx1, which involves the early development of the pancreas and regulates glucose-dependent insulin gene expression [42]. Collectively, these data further demonstrated rs912304 as an islet-specific functional variant.

A prior study revealed that STXBP6 induced by needle-shaped hydroxyapatite (n-nHA)-treated macrophages triggers autophagy, which markedly promotes macrophage fusion into multinucleated giant cells (MNGCs) [43], which implicated STXBP6 as an immune function related gene. Moreover, 14q12 was reported to be a T2D risk region with the leading variant rs11159347 [17]. Using locus-to-gene pipeline (L2G) from Open Targets Genetics [20] prioritized STXBP6 as the most potential causal gene for T2D with the highest L2G score. This study identified STXBP6 as the most putative causal gene in islet beta cells, regulated by the functional T1D risk variant rs912304, independent of rs11159347. Prior studies have demonstrated that the proinflammatory cytokines IFN-γ, IL-1β, and TNF-α are produced mainly by islet-infiltrating immune cells and affect beta cell function and apoptosis, contributing to T1D development [44, 45]. Our study further revealed that STXBP6 was upregulated in islet β-cells under such proinflammatory cytokine stimulation. Consistently, human islets scRNA-seq analysis in the HPAP dataset [27] showed that STXBP6 was increased in islet beta cells of T1D subjects.

Despite its relatively low expression in islet beta cells, STXBP6 could participate in the expansion of fusion pores during the insulin exocytosis process [15, 16] and inhibit glucose-stimulated insulin secretion regulated by SOX4 [15, 16]. Although Glut2 is well recognized as the glucose transporter contributing to insulin secretion [46], this gene was not regulated by Stxbp6 in mouse pancreatic beta cells. However, this study indicated that Glut1, another glucose transporter isoform, was down-regulated by Stxbp6 in islet beta cells, facilitating glucose-stimulated insulin secretion [47]. Moreover, our study suggested that Stxbp6 also promoted islet β cell apoptosis, consistent with the downstream genes of Stxbp6 that were enriched in the p53 pathway. Gadd45β, a typical gene in the p53 pathway, was upregulated by Stxbp6 in islet beta cells and is involved in the positive regulation of the apoptotic process [48, 49]. Interaction networks from GeneMANIA (http://genemania.org/) and STRING (https://cn.string-db.org/) revealed that Stxbp6 might regulate Glut1 and Gadd45β indirectly. As cumulative evidence supported a critical role for β-cells contributing to T1D pathogenesis [11], we speculated that STXBP6 might contribute to T1D pathogenesis via regulating islet function and beta cell apoptosis.

Our study also has several limitations. First, due to the differences in minor allele frequency, LD patterns, and effect size in different populations, no single population is sufficient for fully uncovering the variants underlying T1D in all populations. Thus, studies should further explore the association between rs912304 and late-onset T1D risk in other populations. Second, although Stxbp6 regulated Glut1 and Gadd45β in islet beta cells, the exact contributions of these two genes in mediating the effects of Stxbp6 on beta cell function and survival still need further investigation. Finally, the function of Stxbp6 in the immune regulation related to T1D risk should be further studied, as both innate and adaptive immune abnormalities play critical roles in T1D pathogenesis [50].

Conclusions

In summary, we have identified rs912304 as a functional variant for late-onset T1D risk, affecting residual islet function in newly diagnosed T1D individuals. This variant regulates STXBP6 expression in islet beta cells, a causal gene promoting islet β-cell apoptosis and inhibiting insulin secretion. These findings expanded the genomic landscape regarding T1D risk and prompted the genetic heterogeneity in T1D subgroups with different diagnosed ages. This study also showed the evidence supported a role for β-cells in T1D pathogenesis, which needs further exploration.

Supplementary Information

Additional file 1: Table S1-Table S9. Table S1. The list of primer sequences for q-PCR used in this study. Table S2. The lists of the variants in 14q12 regions associated with T1D risk. Table S3. The association between rs912304 in STXBP6 and late-onset T1D subjects stratified by islet-specific autoantibody status. Table S4. Correlation of rs912304 with residual islet function in newly diagnosed T1D individuals. Table S5. The association between rs912304 and the positive rate of GADA, ZnT8A and IA-2A. Table S6. Identification of the potential functional variants in the suggestive T1D risk regions 14q12 using RegulomeDB. Table S7. The spatial overlaps for potential functional variants in 14q12 with epigenomics datain pancreas and islets. Table S8. The overall variant to genescores implicated by this variant rs912304 by Open Targets Genetics. Table S9. The lists of the representive enriched KEGG and GO pathway in Stxbp6 over-expressed INS-1E cells

Additional file 2: Figures S1-S3. FigS1. Multi-tissue eQTL Plot for rs912304 derived from the GTEx Analysis Release V8 (dbGaP Accession phs000424.v8.p2). FigS2. Expression of STXBP6 gene in pancreas or islets under different conditions in GEO database. FigS3. Validation with qPCR for the potential downstream genes identified by RNA-Seq

Additional file 3. Original blot images

Abbreviations

ATAC-seq The assay for transposase-accessible chromatin using sequencing

CD226 DNAX accessory molecule-1

Cdk2 Cyclin-dependent kinase 2

CI Confidence interval

CIR Corrected insulin response

CLEC16A C-type lectin domain containing 16A

CTLA4 Cytotoxic T lymphocyte-associated antigen-4

CTSH Cathepsin H

Cxcl12 C-X-C motif chemokine ligand 12

Cygb Cytoglobin

DEGs Differentially expressed genes

DI Disposition indexes

ENO2 Enolase 2

eQTL Expression quantitative trait loci

FFA Free fatty acid

FPKM Fragments per kilobase of exon model per million reads mapped

GADA Glutamic acid decarboxylase antibodies

Gadd45β Growth arrest and DNA damage-inducible 45Β

GAPDH Glyceraldehyde-3-phosphate dehydrogenase

GLIS3 Glis family zinc finger 3

Glut1 The glucose transporter type 1

GRS Genetic risk score

GSIS Glucose-stimulated insulin secretion test

GWAS Genome-wide association studies

H3K27ac Histone H3 lysine 27 acetylation

H3K4me1 Histone H3 lysine 4 monomethylation

HbA1C Hemoglobin A1C

HLA Human leukocyte antigen

HOMA-B Homeostasis model assessment of beta-cell function

HOMA-IR Homeostasis model assessment of insulin resistance

HPAP Human pancreas analysis program

HWE Hardy-Weinberg equilibrium

IA-2A Islet antigen 2 antibodies

IFIH1 Interferon induced with helicase C domain 1

IGI Insulinogenic index

IL-1β Interleukin-1Β

IL-2RA Interleukin 2 receptor subunit alpha

INF-γ Interferon-Γ

INS Insulin

ISIMatsuda Insulin sensitivity index of Matsuda

L2G Locus-to-gene pipeline

LD Linkage disequilibrium

MAF Minor allele frequency

MAFF Maf Bzip transcription factor F

MAFK Maf Bzip transcription factor K

Mgarp Mitochondria localized glutamic acid-rich protein

MMTT Mixed meal glucose tolerance test

nPOD The Network For Pancreatic Organ Donors With Diabetes

OGTT Oral glucose tolerance test

OR Odds ratio

PTPN2 Protein tyrosine phosphatase non-receptor type 2

PWM Position weight matrix

RIPA Radio immunoprecipitation assay

scRNA-seq Single-cell RNA sequencing

SD Standard deviation

SEM Standard error of mean

SH2B3 Sh2B adaptor protein 3

siRNA Small/short interfering RNA

Slc2a1 Solute carrier family 2 member 1

SNARE Soluble N-ethylmaleimide-sensitive factor attachment protein receptor

SOX4 SRY-box transcription factor 4

STXBP6 Syntaxin binding protein 6

T1D Type 1 diabetes

T2D Type 2 diabetes

TNF-α Tumor necrosis factor-Α

Tp73 Tumor protein P73

TSS Transcription start site

V2G Variant-to-gene

VEP Variant effect predictor

VRK1 VRK serine/threonine kinase 1

ZnT8A Zinc transporter 8 autoantibody

Acknowledgements

We thank all study participants and the research staff who participated in this work. We appreciate the assistance provided by the Core Facility of the First Affiliated Hospital of Nanjing Medical University in conducting the experiment.

Authors’ contributions

K.X. directed the study design, performed statistical analyses, and drafted the initial manuscript. Q.F. and T.Y. participated in the study design and revised the manuscript. Y.Q., S.C., Y.W. and Y.Z. performed the cell and molecular experiments, reviewed and edited the final manuscript. J.Z., L.J., and Y.H. conducted part of the statistical analyses and revised the manuscript. H.D., M.S. and H.J. performed overall project management and sample processing and carried out laboratory measurements. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (82370839, 81670715, 82070803, and 82200888), Jiangsu Province Youth Medical Talents Project (QNRC2016584), the Natural Science Foundation of Jiangsu Province (BK20220714 and BK2012486).

Availability of data and materials

All data is provided in the manuscript and in the supplementary tables.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

All experiments were approved by the Medical Ethics Committee of the First Affiliated Hospital of Nanjing Medical University (2021-SR-298). Experiments were conducted in accordance with relevant institutional guidelines and regulations.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Yu Qian, Shu Chen, Yan Wang, and Yuyue Zhang contributed equally.
==== Refs
References

1. Griess K Rieck M Müller N Karsai G Hartwig S Pelligra A Sphingolipid subtypes differentially control proinsulin processing and systemic glucose homeostasis Nat Cell Biol 2023 25 1 20 29 10.1038/s41556-022-01027-2 36543979
Griess K, Rieck M, Müller N, Karsai G, Hartwig S, Pelligra A, et al. Sphingolipid subtypes differentially control proinsulin processing and systemic glucose homeostasis. Nat Cell Biol. 2023;25(1):20–9.36543979 10.1038/s41556-022-01027-2
2. Atkinson M Eisenbarth G Michels A Type 1 diabetes Lancet 2014 383 9911 69 82 10.1016/S0140-6736(13)60591-7 23890997
Atkinson M, Eisenbarth G, Michels A. Type 1 diabetes. Lancet (London, England). 2014;383(9911):69–82.23890997 10.1016/S0140-6736(13)60591-7
3. Zheng P Li Z Zhou Z Gut microbiome in type 1 diabetes: a comprehensive review Diabetes Metab Res Rev 2018 34 7 e3043 10.1002/dmrr.3043 29929213
Zheng P, Li Z, Zhou Z. Gut microbiome in type 1 diabetes: a comprehensive review. Diabetes Metab Res Rev. 2018;34(7):e3043.29929213 10.1002/dmrr.3043
4. Geravandi S Liu H Maedler K Enteroviruses and T1D: is it the virus, the genes or both which cause T1D Microorganisms 2020 8 7 1017 10.3390/microorganisms8071017 32650582
Geravandi S, Liu H, Maedler K. Enteroviruses and T1D: Is It the Virus, the Genes or Both which Cause T1D. Microorganisms. 2020;8(7):1017.32650582 10.3390/microorganisms8071017
5. Pociot F Lernmark Å Genetic risk factors for type 1 diabetes Lancet 2016 387 10035 2331 2339 10.1016/S0140-6736(16)30582-7 27302272
Pociot F, Lernmark Å. Genetic risk factors for type 1 diabetes. Lancet (London, England). 2016;387(10035):2331–9.27302272 10.1016/S0140-6736(16)30582-7
6. Barrett J Clayton D Concannon P Akolkar B Cooper J Erlich H Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes Nat Genet 2009 41 6 703 707 10.1038/ng.381 19430480
Barrett J, Clayton D, Concannon P, Akolkar B, Cooper J, Erlich H, et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet. 2009;41(6):703–7.19430480 10.1038/ng.381
7. Onengut-Gumuscu S Chen W Burren O Cooper N Quinlan A Mychaleckyj J Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers Nat Genet 2015 47 4 381 386 10.1038/ng.3245 25751624
Onengut-Gumuscu S, Chen W, Burren O, Cooper N, Quinlan A, Mychaleckyj J, et al. Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. Nat Genet. 2015;47(4):381–6.25751624 10.1038/ng.3245
8. Wang Z Xie Z Lu Q Chang C Zhou Z Beyond genetics: what causes type 1 Diabetes Clin Rev Allergy Immunol 2017 52 2 273 286 10.1007/s12016-016-8592-1 27878451
Wang Z, Xie Z, Lu Q, Chang C, Zhou Z. Beyond genetics: what causes type 1 Diabetes. Clin Rev Allergy Immunol. 2017;52(2):273–86.27878451 10.1007/s12016-016-8592-1
9. Sharma A Liu X Hadley D Hagopian W Chen W Onengut-Gumuscu S Identification of non-HLA genes associated with development of islet autoimmunity and type 1 diabetes in the prospective TEDDY cohort J Autoimmun 2018 89 90 100 10.1016/j.jaut.2017.12.008 29310926
Sharma A, Liu X, Hadley D, Hagopian W, Chen W, Onengut-Gumuscu S, et al. Identification of non-HLA genes associated with development of islet autoimmunity and type 1 diabetes in the prospective TEDDY cohort. J Autoimmun. 2018;89:90–100.29310926 10.1016/j.jaut.2017.12.008
10. Steck A Rewers M Genetics of type 1 diabetes Clin Chem 2011 57 2 176 185 10.1373/clinchem.2010.148221 21205883
Steck A, Rewers M. Genetics of type 1 diabetes. Clin Chem. 2011;57(2):176–85.21205883 10.1373/clinchem.2010.148221
11. Roep B Thomaidou S van Tienhoven R Zaldumbide A Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?) Nat Rev Endocrinol 2021 17 3 150 161 10.1038/s41574-020-00443-4 33293704
Roep B, Thomaidou S, van Tienhoven R, Zaldumbide A. Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?). Nat Rev Endocrinol. 2021;17(3):150–61.33293704 10.1038/s41574-020-00443-4
12. Pociot F Type 1 diabetes genome-wide association studies: not to be lost in translation Clin Transl Immunol 2017 6 12 e162 10.1038/cti.2017.51
Pociot F. Type 1 diabetes genome-wide association studies: not to be lost in translation. Clin Transl Immunol. 2017;6(12):e162.10.1038/cti.2017.51
13. Zhu M Xu K Chen Y Gu Y Zhang M Luo F Identification of novel T1D risk loci and their association with age and islet function at diagnosis in autoantibody-positive T1D individuals: based on a two-stage genome-wide association study Diabetes Care 2019 42 8 1414 1421 10.2337/dc18-2023 31152121
Zhu M, Xu K, Chen Y, Gu Y, Zhang M, Luo F, et al. Identification of novel T1D risk loci and their association with age and islet function at diagnosis in autoantibody-positive T1D individuals: based on a two-stage genome-wide association study. Diabetes Care. 2019;42(8):1414–21.31152121 10.2337/dc18-2023
14. Vinci M Costanza C Galati Rando R Treccarichi S Saccone S Carotenuto M STXBP6 gene mutation: a new form of SNAREopathy leads to developmental epileptic encephalopathy Int J Mol Sci 2023 24 22 16436 10.3390/ijms242216436 38003627
Vinci M, Costanza C, Galati Rando R, Treccarichi S, Saccone S, Carotenuto M, et al. STXBP6 gene mutation: a new form of SNAREopathy leads to developmental epileptic encephalopathy. Int. J. Mol. Sci. 2023;24(22):16436.38003627 10.3390/ijms242216436
15. Rorsman P Ashcroft F Pancreatic β-cell electrical activity and insulin secretion: of mice and men Physiol Rev 2018 98 1 117 214 10.1152/physrev.00008.2017 29212789
Rorsman P, Ashcroft F. Pancreatic β-cell electrical activity and insulin secretion: of mice and men. Physiol Rev. 2018;98(1):117–214.29212789 10.1152/physrev.00008.2017
16. Ragvin A Moro E Fredman D Navratilova P Drivenes Ø Engström P Long-range gene regulation links genomic type 2 diabetes and obesity risk regions to HHEX, SOX4, and IRX3 Proc Natl Acad Sci U S A 2010 107 2 775 780 10.1073/pnas.0911591107 20080751
Ragvin A, Moro E, Fredman D, Navratilova P, Drivenes Ø, Engström P, et al. Long-range gene regulation links genomic type 2 diabetes and obesity risk regions to HHEX, SOX4, and IRX3. Proc Natl Acad Sci U S A. 2010;107(2):775–80.20080751 10.1073/pnas.0911591107
17. Vujkovic M Keaton J Lynch J Miller D Zhou J Tcheandjieu C Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis Nat Genet 2020 52 7 680 91 10.1038/s41588-020-0637-y 32541925
Vujkovic M, Keaton J, Lynch J, Miller D, Zhou J, Tcheandjieu C, et al. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. Nat. Genet. 2020;52(7):680–91.32541925 10.1038/s41588-020-0637-y
18. Dong S Zhao N Spragins E Kagda M Li M Assis P Annotating and prioritizing human non-coding variants with RegulomeDB v.2 Nat Genet 2023 55 5 724 726 10.1038/s41588-023-01365-3 37173523
Dong S, Zhao N, Spragins E, Kagda M, Li M, Assis P, et al. Annotating and prioritizing human non-coding variants with RegulomeDB vol 2. Nat Genet. 2023;55(5):724–6.37173523 10.1038/s41588-023-01365-3
19. Ward L Kellis M HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants Nucleic Acids Res 2012 40 D930 D934 10.1093/nar/gkr917 22064851
Ward L, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 2012;40:D930–4.22064851 10.1093/nar/gkr917
20. Mountjoy E Schmidt E Carmona M Schwartzentruber J Peat G Miranda A An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci Nat Genet 2021 53 11 1527 1533 10.1038/s41588-021-00945-5 34711957
Mountjoy E, Schmidt E, Carmona M, Schwartzentruber J, Peat G, Miranda A, et al. An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci. Nat Genet. 2021;53(11):1527–33.34711957 10.1038/s41588-021-00945-5
21. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science (New York, N.Y.). 2020;369(6509):1318–30.
22. Alonso L Piron A Morán I Guindo-Martínez M Bonàs-Guarch S Atla G TIGEr: the gene expression regulatory variation landscape of human pancreatic islets Cell Rep 2021 37 2 109807 10.1016/j.celrep.2021.109807 34644572
Alonso L, Piron A, Morán I, Guindo-Martínez M, Bonàs-Guarch S, Atla G, et al. TIGEr: the gene expression regulatory variation landscape of human pancreatic islets. Cell Rep. 2021;37(2):109807.34644572 10.1016/j.celrep.2021.109807
23. Jiang H Zheng S Qian Y Zhou Y Dai H Liang Y Restored UBE2C expression in islets promotes β-cell regeneration in mice by ubiquitinating PER1 Cell Mol Life Sci 2023 80 8 226 10.1007/s00018-023-04868-8 37486389
Jiang H, Zheng S, Qian Y, Zhou Y, Dai H, Liang Y, et al. Restored UBE2C expression in islets promotes β-cell regeneration in mice by ubiquitinating PER1. Cell Mol Life Sci. 2023;80(8):226.37486389 10.1007/s00018-023-04868-8
24. Nicholas JT Angus GJ The challenges of identifying and studying type 1 diabetes in adults Diabetologia 2023 66 12 2200 10.1007/s00125-023-06004-4 37728732
Nicholas J T, Angus G J. The challenges of identifying and studying type 1 diabetes in adults. Diabetologia. 2023;66(12):2200.37728732 10.1007/s00125-023-06004-4
25. Varshney A Scott L Welch R Erdos M Chines P Narisu N Genetic regulatory signatures underlying islet gene expression and type 2 diabetes Proc Natl Acad Sci U S A 2017 114 9 2301 2306 10.1073/pnas.1621192114 28193859
Varshney A, Scott L, Welch R, Erdos M, Chines P, Narisu N, et al. Genetic regulatory signatures underlying islet gene expression and type 2 diabetes. Proc Natl Acad Sci U S A. 2017;114(9):2301–6.28193859 10.1073/pnas.1621192114
26. Miguel-Escalada I Bonàs-Guarch S Cebola I Ponsa-Cobas J Mendieta-Esteban J Atla G Human pancreatic islet three-dimensional chromatin architecture provides insights into the genetics of type 2 diabetes Nat Genet 2019 51 7 1137 1148 10.1038/s41588-019-0457-0 31253982
Miguel-Escalada I, Bonàs-Guarch S, Cebola I, Ponsa-Cobas J, Mendieta-Esteban J, Atla G, et al. Human pancreatic islet three-dimensional chromatin architecture provides insights into the genetics of type 2 diabetes. Nat Genet. 2019;51(7):1137–48.31253982 10.1038/s41588-019-0457-0
27. Elgamal R Kudtarkar P Melton R Mummey H Benaglio P Okino M An integrated map of cell type-specific gene expression in pancreatic islets Diabetes 2023 72 11 1719 1728 10.2337/db23-0130 37582230
Elgamal R, Kudtarkar P, Melton R, Mummey H, Benaglio P, Okino M, et al. An integrated map of cell type-specific gene expression in pancreatic islets. Diabetes. 2023;72(11):1719–28.37582230 10.2337/db23-0130
28. Harding J Wander P Zhang X Li X Karuranga S Chen H The incidence of adult-onset type 1 diabetes: a systematic review from 32 countries and regions Diabetes Care 2022 45 4 994 1006 10.2337/dc21-1752 35349653
Harding J, Wander P, Zhang X, Li X, Karuranga S, Chen H, et al. The incidence of adult-onset type 1 diabetes: a systematic review from 32 countries and regions. Diabetes Care. 2022;45(4):994–1006.35349653 10.2337/dc21-1752
29. Redondo M Concannon P Genetics of type 1 diabetes comes of age Diabetes Care 2020 43 1 16 18 10.2337/dci19-0049 31862821
Redondo M, Concannon P. Genetics of type 1 diabetes comes of age. Diabetes Care. 2020;43(1):16–8.31862821 10.2337/dci19-0049
30. Inshaw J Cutler A Crouch D Wicker L Todd J Genetic variants predisposing most strongly to type 1 diabetes diagnosed under age 7 years lie near candidate genes that function in the immune system and in pancreatic β-cells Diabetes Care 2020 43 1 169 177 10.2337/dc19-0803 31558544
Inshaw J, Cutler A, Crouch D, Wicker L, Todd J. Genetic variants predisposing most strongly to type 1 diabetes diagnosed under age 7 years lie near candidate genes that function in the immune system and in pancreatic β-cells. Diabetes Care. 2020;43(1):169–77.31558544 10.2337/dc19-0803
31. Inshaw J Walker N Wallace C Bottolo L Todd J The chromosome 6q22.33 region is associated with age at diagnosis of type 1 diabetes and disease risk in those diagnosed under 5 years of age Diabetologia 2018 61 1 147 57 10.1007/s00125-017-4440-y 28983737
Inshaw J, Walker N, Wallace C, Bottolo L, Todd J. The chromosome 6q22.33 region is associated with age at diagnosis of type 1 diabetes and disease risk in those diagnosed under 5 years of age. Diabetologia. 2018;61(1):147–57.28983737 10.1007/s00125-017-4440-y
32. Steck A Xu P Geyer S Redondo M Antinozzi P Wentworth J Can non-HLA single nucleotide polymorphisms help stratify risk in trialnet relatives at risk for type 1 diabetes? J Clin Endocrinol Metab 2017 102 8 2873 2880 10.1210/jc.2016-4003 28520980
Steck A, Xu P, Geyer S, Redondo M, Antinozzi P, Wentworth J, et al. Can non-HLA single nucleotide polymorphisms help stratify risk in trialnet relatives at risk for type 1 diabetes? J Clin Endocrinol Metab. 2017;102(8):2873–80.28520980 10.1210/jc.2016-4003
33. Törn C Hadley D Lee H Hagopian W Lernmark Å Simell O Role of type 1 diabetes-associated SNPs on risk of autoantibody positivity in the TEDDY study Diabetes 2015 64 5 1818 1829 10.2337/db14-1497 25422107
Törn C, Hadley D, Lee H, Hagopian W, Lernmark Å, Simell O, et al. Role of type 1 diabetes-associated SNPs on risk of autoantibody positivity in the TEDDY study. Diabetes. 2015;64(5):1818–29.25422107 10.2337/db14-1497
34. Plagnol V Howson J Smyth D Walker N Hafler J Wallace C Genome-wide association analysis of autoantibody positivity in type 1 diabetes cases PLoS Genet 2011 7 8 e1002216 10.1371/journal.pgen.1002216 21829393
Plagnol V, Howson J, Smyth D, Walker N, Hafler J, Wallace C, et al. Genome-wide association analysis of autoantibody positivity in type 1 diabetes cases. PLoS Genet. 2011;7(8): e1002216.21829393 10.1371/journal.pgen.1002216
35. Fløyel T Brorsson C Nielsen L Miani M Bang-Berthelsen C Friedrichsen M CTSH regulates β-cell function and disease progression in newly diagnosed type 1 diabetes patients Proc Natl Acad Sci U S A 2014 111 28 10305 10310 10.1073/pnas.1402571111 24982147
Fløyel T, Brorsson C, Nielsen L, Miani M, Bang-Berthelsen C, Friedrichsen M, et al. CTSH regulates β-cell function and disease progression in newly diagnosed type 1 diabetes patients. Proc Natl Acad Sci U S A. 2014;111(28):10305–10.24982147 10.1073/pnas.1402571111
36. Hindorff L Sethupathy P Junkins H Ramos E Mehta J Collins F Potential etiologic and functional implications of genome-wide association loci for human diseases and traits Proc Natl Acad Sci U S A 2009 106 23 9362 9367 10.1073/pnas.0903103106 19474294
Hindorff L, Sethupathy P, Junkins H, Ramos E, Mehta J, Collins F, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A. 2009;106(23):9362–7.19474294 10.1073/pnas.0903103106
37. Soranzo N Sanna S Wheeler E Gieger C Radke D Dupuis J Common variants at 10 genomic loci influence hemoglobin A1(C) levels via glycemic and nonglycemic pathways Diabetes 2010 59 12 3229 3239 10.2337/db10-0502 20858683
Soranzo N, Sanna S, Wheeler E, Gieger C, Radke D, Dupuis J, et al. Common variants at 10 genomic loci influence hemoglobin A1(C) levels via glycemic and nonglycemic pathways. Diabetes. 2010;59(12):3229–39.20858683 10.2337/db10-0502
38. Westra H Martínez-Bonet M Onengut-Gumuscu S Lee A Luo Y Teslovich N Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1 diabetes Nat Genet 2018 50 10 1366 1374 10.1038/s41588-018-0216-7 30224649
Westra H, Martínez-Bonet M, Onengut-Gumuscu S, Lee A, Luo Y, Teslovich N, et al. Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1 diabetes. Nat Genet. 2018;50(10):1366–74.30224649 10.1038/s41588-018-0216-7
39. Robertson C Inshaw J Onengut-Gumuscu S Chen W Santa Cruz D Yang H Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes Nat Genet 2021 53 7 962 971 10.1038/s41588-021-00880-5 34127860
Robertson C, Inshaw J, Onengut-Gumuscu S, Chen W, Santa Cruz D, Yang H, et al. Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes. Nat Genet. 2021;53(7):962–71.34127860 10.1038/s41588-021-00880-5
40. Chen M Raffield L Mousas A Sakaue S Huffman J Moscati A Trans-ethnic and ancestry-specific blood-cell genetics in 746,667 individuals from 5 global populations Cell 2020 182 5 1198 213.e14 10.1016/j.cell.2020.06.045 32888493
Chen M, Raffield L, Mousas A, Sakaue S, Huffman J, Moscati A, et al. Trans-ethnic and ancestry-specific blood-cell genetics in 746,667 individuals from 5 global populations. Cell. 2020;182(5):1198-213.e14.32888493 10.1016/j.cell.2020.06.045
41. Bensellam M Montgomery M Luzuriaga J Chan J Laybutt D Inhibitor of differentiation proteins protect against oxidative stress by regulating the antioxidant-mitochondrial response in mouse beta cells Diabetologia 2015 58 4 758 770 10.1007/s00125-015-3503-1 25636209
Bensellam M, Montgomery M, Luzuriaga J, Chan J, Laybutt D. Inhibitor of differentiation proteins protect against oxidative stress by regulating the antioxidant-mitochondrial response in mouse beta cells. Diabetologia. 2015;58(4):758–70.25636209 10.1007/s00125-015-3503-1
42. Gauthier B Wiederkehr A Baquié M Dai C Powers A Kerr-Conte J PDX1 deficiency causes mitochondrial dysfunction and defective insulin secretion through TFAM suppression Cell Metab 2009 10 2 110 118 10.1016/j.cmet.2009.07.002 19656489
Gauthier B, Wiederkehr A, Baquié M, Dai C, Powers A, Kerr-Conte J, et al. PDX1 deficiency causes mitochondrial dysfunction and defective insulin secretion through TFAM suppression. Cell Metab. 2009;10(2):110–8.19656489 10.1016/j.cmet.2009.07.002
43. Siyu C Zhengyi X Mengyu G Rui Z Xiao Y Xiangdong Z Macrophage fusion event as one prerequisite for inorganic nanoparticle-induced antitumor response Sci Adv 2023 9 29 eadd9871 10.1126/sciadv.add9871 37467339
Siyu C, Zhengyi X, Mengyu G, Rui Z, Xiao Y, Xiangdong Z, et al. Macrophage fusion event as one prerequisite for inorganic nanoparticle-induced antitumor response. Sci Adv. 2023;9(29):eadd9871.37467339 10.1126/sciadv.add9871
44. Eizirik D Colli M Ortis F The role of inflammation in insulitis and beta-cell loss in type 1 diabetes Nat Rev Endocrinol 2009 5 4 219 226 10.1038/nrendo.2009.21 19352320
Eizirik D, Colli M, Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol. 2009;5(4):219–26.19352320 10.1038/nrendo.2009.21
45. Ramos-Rodríguez M Raurell-Vila H Colli M Alvelos M Subirana-Granés M Juan-Mateu J The impact of proinflammatory cytokines on the β-cell regulatory landscape provides insights into the genetics of type 1 diabetes Nat Genet 2019 51 11 1588 1595 10.1038/s41588-019-0524-6 31676868
Ramos-Rodríguez M, Raurell-Vila H, Colli M, Alvelos M, Subirana-Granés M, Juan-Mateu J, et al. The impact of proinflammatory cytokines on the β-cell regulatory landscape provides insights into the genetics of type 1 diabetes. Nat Genet. 2019;51(11):1588–95.31676868 10.1038/s41588-019-0524-6
46. Bernard T GLUT2, glucose sensing and glucose homeostasis Diabetologia 2014 58 2 221 25421524
Bernard T. GLUT2, glucose sensing and glucose homeostasis. Diabetologia. 2014;58(2):221.25421524
47. Thorens B Guillam M Beermann F Burcelin R Jaquet M Transgenic reexpression of GLUT1 or GLUT2 in pancreatic beta cells rescues GLUT2-null mice from early death and restores normal glucose-stimulated insulin secretion J Biol Chem 2000 275 31 23751 23758 10.1074/jbc.M002908200 10823833
Thorens B, Guillam M, Beermann F, Burcelin R, Jaquet M. Transgenic reexpression of GLUT1 or GLUT2 in pancreatic beta cells rescues GLUT2-null mice from early death and restores normal glucose-stimulated insulin secretion. J Biol Chem. 2000;275(31):23751–8.10823833 10.1074/jbc.M002908200
48. Takekawa M Saito H A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK Cell 1998 95 4 521 10.1016/S0092-8674(00)81619-0 9827804
Takekawa M, Saito H. A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. Cell. 1998;95(4):521.9827804 10.1016/S0092-8674(00)81619-0
49. Mi-Young K Eun Ji S Dong Ha L Eun Joo K Hye Soo K Hea-Young C Gadd45beta is a novel mediator of cardiomyocyte apoptosis induced by ischaemia/hypoxia Cardiovasc Res 2010 87 1 119 10.1093/cvr/cvq048 20154065
Mi-Young K, Eun Ji S, Dong Ha L, Eun Joo K, Hye Soo K, Hea-Young C, et al. Gadd45beta is a novel mediator of cardiomyocyte apoptosis induced by ischaemia/hypoxia. Cardiovasc Res. 2010;87(1):119.20154065 10.1093/cvr/cvq048
50. Kevan CH Thomas D Ana Luisa P Noah B Todd MB Lucy SKW The immunology of type 1 diabetes Nat Rev Immunol 2024 24 6 435 10.1038/s41577-023-00985-4 38308004
Kevan CH, Thomas D, Ana Luisa P, Noah B, Todd MB, Lucy SKW. The immunology of type 1 diabetes. Nat Rev Immunol. 2024;24(6):435.38308004 10.1038/s41577-023-00985-4
